Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Other

TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network

By The Northwire Desk — AI Analysis Jan 06, 2026 · 17:01 VIVI · 1.24 TempraMed Technologies Ltd.
VIVI · Price

Executive Summary

  • TempraMed Technologies Ltd. announced its first commercial order in Israel, delivering an initial shipment to Guri A.A.O., a leading Israeli medical distributor.
  • The deal adds a B2B distribution channel to TempraMed’s go‑to‑market strategy, expanding the company’s presence in the Israeli pharmacy retail market.
  • Management highlighted this milestone as a key step toward broader international expansion and increased market penetration for its temperature‑controlled medication solutions.

Key Details

  • Partner: Guri A.A.O., among Israel’s top five medical distributors with relationships to 2,500 supermarkets, pharmacy chains, HMOs, and independent pharmacies.
  • Order Scope: First commercial order; initial shipment delivered to Guri’s warehouse (quantity and monetary value not disclosed).
  • Strategic Impact: Introduces a dedicated B2B layer complementing TempraMed’s existing direct‑to‑consumer activities, enabling wider access to its VIVI technology across Israel’s brick‑and‑mortar pharmacy network.
  • Market Context: Israel’s healthcare market is advanced with high adoption of injectable therapies (insulin, GLP‑1 agonists, biologics, emergency meds), driving demand for temperature‑sensitive medication protection.
  • Operational Readiness: Successful delivery demonstrates the company’s capability to support retail pharmacy distribution and sets the foundation for nationwide rollout.
  • Management Quote: CEO Ron Nagar stated the order marks a “leap from being a purely online retailer to physical stores” and underscores TempraMed’s progress toward its 2026 growth objectives.

Notable Quotes

“This first commercial order and delivery to Guri marks an important operational and commercial milestone for TempraMed,” said Ron Nagar, CEO of TempraMed. “We are making the leap from being a purely online retailer to physical stores… We have ambitious plans for 2026 and are well on our way to realizing our own vision, as well as that of our shareholders.”

Read the original news release →

More from TempraMed Technologies Ltd.

Jun 30, 2026 · 03:06

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

M&A / Property Jun 26, 2026 · 16:11

Pioneering passive thermal protection for temperature-sensitive injectables amid aggressive global distribution expansion.

M&A / Property Jun 04, 2026 · 07:01

TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Other May 22, 2026 · 11:58

TempraMed Technologies Ltd.

Other May 14, 2026 · 03:01

Indian patent adds IP depth but revenue-sharing financing signals cash crunch

Financings Apr 07, 2026 · 07:01

Brazilian patent bolsters TempraMed’s IP moat ahead of VIVI Box launch.

M&A / Property